ADIPO-BRAIN Cognitive axis: When the adipose genes control the mind. Integrative analysis of human adipose-specific genes and cognitive function.

ADN tumoral circulante como predictor de recaída en pacientes con cáncer de recto localmente avanzado tratados con terapia neoadyuvante total seguida de observación y espera o escisión total del mesorrecto basada en la evaluación clínica de la respuesta.

Advance Care Planning in Mental Healt: Context, Training Effectiveness, and Feasibility

Afectació coxofemoral de la Hiperostosi esquelètica difusa Idiopàtica.

Alfabetització per la salut en els pacients amb hemodiàlisis.

Alimentació, equilibri ecològic i regulació de la inflamació

An Exploratory, Multi-Centre, Interventional, Prospective, Randomised, Double-Blind, Placebo-Controlled Clinical Trial to Assess the Safety and Efficacy of AON-D21 in Patients with Severe Community-Acquired Pneumonia.

An international multi-centre long term follow up study of the long term outcomes and impact of cancer treatments in triple negative breast cancer.

An interventional, Phase 3 extension study to investigate long-term safety and tolerability of tolebrutinib in participants with relapsing multiple sclerosis, primary progressive multiple sclerosis, or nonrelapsing secondary progressive multiple sclerosis

An Observational, Multicenter Retrospective Cohort Study Involving the Review of Medical Records to Describe the Clinical Characteristics, Treatment Patterns and Clinical Outcomes of Patients with HR+, HER2- Metastatic Breast Cancer in Recent Routine Clinical Practice in Europe.

An open label Phase II randomized trial of BNT113 in combination with pembrolizumab versus pembrolizumab monotherapy as a first line therapy in patients with unresectable recurrent, or metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) which is positive for human papilloma virus 16 (HPV16+) and expresses PD-L1.

AN OPEN-LABEL, 3-ARM, MULTICENTER, RANDOMIZED PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ELRANATAMAB (PF-06863135) MONOTHERAPY AND ELRANATAMAB + DARATUMUMAB VERSUS DARATUMUMAB + POMALIDOMIDE + DEXAMETHASONE IN PARTICIPANTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST 2 PRIOR LINES OF THERAPY INCLUDING LENALIDOMIDE AND A PROTEASOME INHIBITOR

An Open-Label, Multi-Center, Global Study to Evaluate Long Term Safety and Efficacy in Patients Who are Receiving or Who Previously Received Durvalumab in Other Protocols (WAVE)

An Open-label, Multicenter, Phase 2 trial of selinexor (KPT-330), bortezomib and low-dose dexamethasone plus daratumumab (SELIBORDARA) for the treatment of patients with refractory or relapsed and refractory multiple myeloma

An open-label, multicenter, randomized Phase 2 study of the ATR inhibitor tuvusertib in combination with the PARP inhibitor niraparib or the ATM inhibitor lartesertib in participants with BRCA mutant and/or homologous recombination deciency (HRD) positive epithelial ovarian cancer that progressed on prior PARP inhibitor therapy (DDRiver EOC 302)

AN OPEN-LABEL, PHASE 1B STUDY OF SL-172154 (SIRP?-FC CD40L) ADMINISTERED WITH EITHER PEGYLATED LIPOSOMAL DOXORUBICIN OR MIRVETUXIMAB SORAVTANSINE IN SUBJECTS WITH PLATINUM-RESISTANT OVARIAN CANCERS

AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPd), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3)

An Ophthalmic Safety Study of Camizestrant in ER+/HER2- Early Breast Cancer Patients Treated within the CAMBRIA-1 or CAMBRIA-2 Studies

Anàlisi comparatiu de l'empremta de carboni generada en la cirurgia colorectal mínimament invasiva: laparoscòpica vs. robòtica

Anàlisi comparativa de dues estratègies de recanvi eritrocitari en la drepanocitosi: recanvi amb hemodilució isovolèmica i recanvi simple